Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613565 | 1.00 | RORC (0.36) | RORCKCNH2PTGDR2MGLLFAAH | |
| SCHEMBL29613551 | 0.88 | PTGDR2 (0.38) | RORCKCNH2PTGDR2MGLLFAAH | |
| SCHEMBL19785781 | 0.88 | PTGDR2 (0.38) | RORCKCNH2PTGDR2MGLLFAAH | |
| SCHEMBL29613571 | 0.87 | MAP4K4 (0.37) | RORCKCNH2PTGDR2 | |
| SCHEMBL19785606 | 0.87 | MAP4K4 (0.37) | RORCKCNH2PTGDR2 | |
| SCHEMBL21354323 | 0.87 | RORC (0.41) | RORCKCNH2PTGDR2MGLLFAAH | |
| SCHEMBL19785590 | 0.86 | PTGDR2 (0.44) | RORCKCNH2PTGDR2 | |
| SCHEMBL29613591 | 0.86 | PTGDR2 (0.44) | RORCKCNH2PTGDR2 | |
| SCHEMBL21368990 | 0.85 | ALDH1A1 (0.42) | RORCKCNH2PTGDR2 | |
| SCHEMBL29613556 | 0.85 | ALDH1A1 (0.42) | RORCKCNH2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476653-B | Heteroaromatic modulators of retinoid-related orphan receptor gamma | 利奥制药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RORA, NR1H3 | RORC 18/4885KCNH2 2774/4885PTGDR2 328/4885 |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | RORC 17/4885KCNH2 1887/4885PTGDR2 434/4885 |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | RORC 17/4885KCNH2 1887/4885PTGDR2 434/4885 |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RXRG, RXRB | RORC 17/4885KCNH2 1887/4885PTGDR2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.